We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+9.96%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.79B
AUM Growth
-$56M
Cap. Flow
-$584M
Cap. Flow %
-20.93%
Top 10 Hldgs %
31.86%
Holding
129
New
19
Increased
19
Reduced
27
Closed
26

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$67.9M
2
XENT
Intersect ENT, Inc
XENT
+$33.9M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$32.9M
4
NVRO
NEVRO CORP.
NVRO
+$32.8M
5
ACHC icon
Acadia Healthcare
ACHC
+$27.2M

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$130M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$80M
3
AET
Aetna Inc
AET
+$42M
4
CVS icon
CVS Health
CVS
+$39.3M
5
WBA
Walgreens Boots Alliance
WBA
+$31.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.65%
2 Financials 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFNX
76
DELISTED
Pfenex Inc.
PFNX
$5.46M 0.2%
1,069,514
-60,170
-5% -$309K
GWPH
77
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.05M 0.18%
29,249
-203,751
-87% -$29.4M
ADUS icon
78
Addus HomeCare
ADUS
$2.15B
$4.6M 0.16%
+65,590
New +$4.25M
CNST
79
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$4.28M 0.15%
+635,843
New +$6.06M
EIDX
80
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$4.2M 0.15%
420,409
+96,602
+30% +$1.59M
ALBO
81
DELISTED
Albireo Pharma Inc
ALBO
$3.96M 0.14%
120,000
– –
ALPN
82
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.88M 0.14%
612,867
-300,233
-33% -$2.1M
OPCH icon
83
Option Care Health
OPCH
$3.41B
$3.17M 0.11%
255,845
-327,905
-56% -$3.84M
TLGT
84
DELISTED
Teligent, Inc
TLGT
$2.8M 0.1%
70,887
– –
SVRA icon
85
Savara
SVRA
$1.12B
$2.79M 0.1%
+250,000
New +$2.88M
TARA icon
86
Protara Therapeutics
TARA
$230M
$2.39M 0.09%
30,622
– –
VTAK icon
87
Catheter Precision
VTAK
$1.7M
$2.34M 0.08%
+1
New +$4.54M
VYGR icon
88
Voyager Therapeutics
VYGR
$189M
$2.23M 0.08%
117,647
– –
KIDS icon
89
OrthoPediatrics
KIDS
$503M
$2.13M 0.08%
58,247
-22,536
-28% -$690K
FOMX
90
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.34M 0.05%
234,745
-439,257
-65% -$2.51M
HYPD
91
Hyperion DeFi Inc
HYPD
$42.3M
$1.21M 0.04%
3,750
– –
PTX
92
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$635K 0.02%
+658,826
New +$1.1M
OCGN icon
93
Ocugen
OCGN
$450M
$161K 0.01%
+4,935
New +$571K
ALNY icon
94
Alnylam Pharmaceuticals
ALNY
$36.4B
– –
-146,000
Closed -$14.4M
CVS icon
95
CVS Health
CVS
$137B
– –
-550,000
Closed -$39.3M
DXCM icon
96
DexCom
DXCM
$29.5B
– –
-660,700
Closed -$15.7M
ECOR icon
97
electroCore
ECOR
$50.4M
– –
-28,362
Closed -$7.02M
MNKD icon
98
MannKind Corp
MNKD
$1.24B
– –
-1,458,537
Closed -$2.77M
MOH icon
99
Molina Healthcare
MOH
$12B
– –
-168,000
Closed -$16.5M
NTRA icon
100
Natera
NTRA
$38.1B
– –
-1,080,829
Closed -$20.3M
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2018 Portfolio in Review

As of Q3 2018, Deerfield Management held 129 positions worth $2.79B, down 2% from $2.85B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Deerfield Management withdrew a net $584M in Q3 2018, closing 26 positions and reducing 27 holdings. Its most notable exit was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $130M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 74% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in NEVRO CORP. worth $29.9M.

  • Deerfield Management's largest Q3 2018 buy was NEVRO CORP.: 525,040 shares worth $29.9M.
  • Deerfield Management added most to Aerie Pharmaceuticals in Q3 2018, an estimated $67.9M increase.
  • Deerfield Management's biggest Q3 2018 reduction was Tandem Diabetes Care, cutting an estimated $80M.
  • Deerfield Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2018, selling an estimated $130M.
  • Deerfield Management's ten largest holdings make up 32% of its $2.79B portfolio in Q3 2018.
  • Deerfield Management opened 19 new positions and closed 26 in Q3 2018.
  • Deerfield Management's portfolio value fell 2% quarter-over-quarter to $2.79B.

Based on Deerfield Management's 13F filing for Q3 2018, filed 14 Nov 2018.